Video
Author(s):
Focusing on clinical trials and novel therapies, Rami Komrokji, MD, and Ruben Mesa, MD, share their hope for the future management of essential thrombocythemia and polycythemia vera.
Jakafi May Not Associate with Long-Term Benefits in Myelofibrosis Subset
FDA Stops Lung Cancer Trial, CAR-T Cell Therapy Is Cost Effective, Novel Drug Slows Fibrosis
Subcutaneous Dacogen Elicits Responses Among Some With Myelofibrosis
LeVar Burton Helping the MPN Community Through Advocacy and Storytelling
Empowering Patients With Cancer Through Clear Clinical Trial Communication
Ryoncil Receives FDA Approval for Children With GVHD